EE200100600A - FAP-aktiveeritud kasvajavastased ühendid - Google Patents

FAP-aktiveeritud kasvajavastased ühendid

Info

Publication number
EE200100600A
EE200100600A EEP200100600A EEP200100600A EE200100600A EE 200100600 A EE200100600 A EE 200100600A EE P200100600 A EEP200100600 A EE P200100600A EE P200100600 A EEP200100600 A EE P200100600A EE 200100600 A EE200100600 A EE 200100600A
Authority
EE
Estonia
Prior art keywords
fap
antitumor compounds
activated antitumor
activated
compounds
Prior art date
Application number
EEP200100600A
Other languages
English (en)
Estonian (et)
Inventor
Carin-Chesa Pilar
Lenter Martin
Edward Park John
Peters Stefan
J. Rettig Wolfgang
Armand Firestone Raymond
Leipert Dietmar
Mack J�rgen
A. Telan Leila
Original Assignee
Boehringer Ingelheim Pharma Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg
Publication of EE200100600A publication Critical patent/EE200100600A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100600A 1999-05-14 2000-05-11 FAP-aktiveeritud kasvajavastased ühendid EE200100600A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13413699P 1999-05-14 1999-05-14
PCT/EP2000/004261 WO2000071571A2 (en) 1999-05-14 2000-05-11 Fap-activated anti-tumor compounds

Publications (1)

Publication Number Publication Date
EE200100600A true EE200100600A (et) 2003-02-17

Family

ID=22461925

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100600A EE200100600A (et) 1999-05-14 2000-05-11 FAP-aktiveeritud kasvajavastased ühendid

Country Status (28)

Country Link
US (1) US6613879B1 (uk)
EP (1) EP1180116A2 (uk)
JP (1) JP3607201B2 (uk)
KR (1) KR20020030270A (uk)
CN (1) CN1213058C (uk)
AR (1) AR033792A1 (uk)
AU (1) AU777521B2 (uk)
BG (1) BG106096A (uk)
BR (1) BR0010564A (uk)
CA (1) CA2369933A1 (uk)
CO (1) CO5170516A1 (uk)
CZ (1) CZ20014097A3 (uk)
EA (1) EA005204B1 (uk)
EE (1) EE200100600A (uk)
HK (1) HK1048642B (uk)
HU (1) HUP0202367A3 (uk)
IL (1) IL145798A0 (uk)
MX (1) MXPA01011401A (uk)
MY (1) MY125939A (uk)
NO (1) NO20015536L (uk)
NZ (1) NZ516075A (uk)
PL (1) PL351680A1 (uk)
SK (1) SK16452001A3 (uk)
TW (1) TWI248444B (uk)
UA (1) UA73506C2 (uk)
WO (1) WO2000071571A2 (uk)
YU (1) YU80901A (uk)
ZA (1) ZA200109151B (uk)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001245836A1 (en) 2000-03-15 2002-07-16 Bristol-Myers Squibb Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
GB0027551D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
CA2447470A1 (en) * 2001-05-09 2002-11-14 Newbiotics, Inc. Peptide deformylase activated prodrugs
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20030211979A1 (en) * 2002-01-30 2003-11-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor compounds
EP1333033A1 (en) * 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
EP1499318A4 (en) * 2002-04-18 2006-07-19 Celmed Oncology Usa Inc ACTIVE PROMEDIAMENTS BY PEPTIDE DEFORMYLASE
US20040033957A1 (en) * 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
WO2003094972A2 (en) * 2002-05-10 2003-11-20 Boehringer Ingelheim Pharma Gmbh & Co Kg Fap-activated anti-tumor prodrugs
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
TW200418508A (en) * 2002-11-14 2004-10-01 Newbiotics Inc Peptide deformylase activated prodrugs
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
AU2006246719A1 (en) * 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EP1963537A4 (en) * 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS BY DETERMINING FIBROBLASTIC SYNOVIOCYTES FOR FIBROBLAST ACTIVATION PROTEIN
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008005479A2 (en) * 2006-07-06 2008-01-10 University Of Wyoming Charge reversible polymers
WO2008116053A2 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
JP5781930B2 (ja) * 2008-09-12 2015-09-24 カディラ ファーマシューティカルズ リミテッド 新規なジペプチジルペプチダーゼ（ｄｐ−ｉｖ）化合物
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20150335761A1 (en) * 2012-02-16 2015-11-26 Raymond Firestone Compositions and methods for contraception
CN113476616A (zh) 2012-12-28 2021-10-08 科比欧尔斯公司 最低毒性的药物前体
WO2014169697A1 (zh) * 2013-04-19 2014-10-23 暨南大学 长春碱类衍生物及其制备方法和应用
PL3066091T3 (pl) * 2013-11-05 2019-10-31 Astrazeneca Ab Proleki antagonisty nmda
WO2015192124A1 (en) * 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
CN113956325A (zh) 2014-06-13 2022-01-21 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
CN105524141B (zh) * 2015-11-12 2019-11-26 中山大学 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
CN110128501A (zh) * 2019-05-21 2019-08-16 北京海美源医药科技有限公司 一种靶向fap酶的喜树碱类化合物及其制备方法和应用
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
FR2546163B1 (fr) 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5047401A (en) * 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
EP0255341B1 (en) 1986-07-29 1993-02-03 Sunstar Kabushiki Kaisha Reagent for testing periodontal diseases
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
AU708475B2 (en) 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
CA2256669A1 (en) 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
EP1144011B1 (en) 1998-12-11 2010-03-10 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2000064486A2 (en) 1999-04-28 2000-11-02 Vectramed, Inc. Enzymatically activated polymeric drug conjugates

Also Published As

Publication number Publication date
PL351680A1 (en) 2003-06-02
CZ20014097A3 (cs) 2002-02-13
NO20015536L (no) 2002-01-10
CO5170516A1 (es) 2002-06-27
AR033792A1 (es) 2004-01-07
AU777521B2 (en) 2004-10-21
YU80901A (sh) 2005-07-19
NZ516075A (en) 2004-03-26
WO2000071571A8 (en) 2002-03-07
JP2003500417A (ja) 2003-01-07
HUP0202367A3 (en) 2003-10-28
BR0010564A (pt) 2002-02-19
UA73506C2 (en) 2005-08-15
MXPA01011401A (es) 2002-06-04
ZA200109151B (en) 2002-12-17
CA2369933A1 (en) 2000-11-30
EA005204B1 (ru) 2004-12-30
JP3607201B2 (ja) 2005-01-05
EA200101155A1 (ru) 2002-10-31
WO2000071571A3 (en) 2001-09-07
NO20015536D0 (no) 2001-11-13
IL145798A0 (en) 2002-07-25
EP1180116A2 (en) 2002-02-20
MY125939A (en) 2006-09-29
AU6559100A (en) 2000-12-12
HK1048642A1 (en) 2003-04-11
CN1374969A (zh) 2002-10-16
BG106096A (bg) 2002-05-31
CN1213058C (zh) 2005-08-03
HK1048642B (zh) 2005-10-28
TWI248444B (en) 2006-02-01
WO2000071571A2 (en) 2000-11-30
HUP0202367A2 (hu) 2002-11-28
US6613879B1 (en) 2003-09-02
SK16452001A3 (sk) 2002-03-05
KR20020030270A (ko) 2002-04-24

Similar Documents

Publication Publication Date Title
EE200100600A (et) FAP-aktiveeritud kasvajavastased ühendid
EE200100502A (et) Ühendid
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
ATA51899A (de) Handstempel
EE200200224A (et) Uudsed ühendid
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
PT1218009E (pt) Grandulos de quetiapina
PT1218096E (pt) Microcapsulas de libertacao variavel
NO20013769L (no) Kalsilytiske forbindelser
PT1163256E (pt) Hemi-hidrato de 16-alfa-bromoepiandrosterona
PT1235566E (pt) Formulacao injectavel de valnemulina
NO20020466D0 (no) Kalsilytiske forbindelser
DE10085008T1 (de) Oberflächenbehandlungsdüse
NO20014262D0 (no) Tiazoloindolinon-forbindelser
DE10082008D2 (de) Ausbeulgerät
ATE269311T1 (de) Benzoylpyridazine
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter
ID29984A (id) Senyawa-senyawa bis-stirilbifenil
PT1190776E (pt) Pulverizador de liquidos
ATA732000A (de) Kachelofen
AT500658A3 (de) Isolierplatte
SE9901271D0 (sv) Novel compounds

Legal Events

Date Code Title Description
HC1A Change of owner name